From Code to Cure: Compugen’s Novel Cancer Immunotherapy Pipeline Derived from its AI/ML-Powered Computational PlatformAstraZeneca

Company name Compugen * Website cgen.com* CEO name: Eran Ophir, PhD

cutive Summary Compugen is a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML. Compugen has 4 clinical stage immune-oncology programs – 2 wholly owned programs developed internally and 2 partnered programs; an AI/ML powered discovery platform; 2 strategic partnerships with big-pharma; an undisclosed early-stage pipeline and cash runway into 2029 ($145.6M as of 31.12.25). Core Technology Compugen immunotherapy proprietary therapeutic pipeline is based on its UnigenTM AI/ML powered predictive computational discovery platform. Unigen integrates AI/ML with human expertise in a continuously enriched flexible-loop platform. It combines Compugen’s deep scientific knowledge, AI/ML predictive algorithms and a cloud-based, technology-agnostic platform integrating a variety of biological datasets to enable discovery of novel drug targets and potential first-in-class cancer immunotherapies. Product Profile/Pipeline Compugen has two proprietary product candidates in Phase 1 developed internally: COM701, potential first-in-class anti-PVRIG antibody and COM902, differentiated anti-TIGIT with a non-active Fc tail for the treatment of solid tumors, which value is reinforced by strategic collaboration with AstraZeneca. Also, the Company’s therapeutic pipeline of earlystage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. Business Strategy Compugen partners its pipeline under licensing agreements. Rilvegostomig, PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s COM902, is developed by AstraZeneca through a license agreement and is undergoing 10 Phase 3 clinical trials. AstraZeneca's targeting >$5bn peak year revenue for Rilvegostomig. GS-0321, potential first-in-class, high affinity anti-IL-18 binding protein antibody, in Phase 1, is licensed to Gilead. What's Next? Data readouts from rilvegostomig in 2026. Advancing Phase 1 trial of GS-0321, anti-IL18BP antibody licensed to Gilead utilizing differentiated cytokine-based approach. Interim analysis of COM701 MAIA-ovarian Phase 1 trial as maintenance therapy in platinum sensitive ovarian cancer in Q1 2027. Partnerships with AstraZeneca and Gilead represent up to $1 billion in potential milestone payments in addition to future royalties.